加味连理汤预防伊立替康致大肠癌患者迟发性腹泻临床研究

Study on Jiawei Lianli Decoction Preventing Irinotecan-Induced Delayed-Onset Diarrhea

目的:观察加味连理汤预防伊立替康(CPT-11)所致迟发性腹泻的效果。方法:将应用FOLFIRI方案治疗的62例晚期大肠癌患者随机分组,治疗组30例在化疗的同时口服加味连理汤至化疗第10天,对照组32例单纯应用化疗,观察患者治疗前后迟发性腹泻的发生情况及严重程度、肿瘤缓解率、健康状况(Karnofsky评分,KPS评分)、免疫功能的变化。结果:治疗组迟发性腹泻的发生率及严重程度明显低于对照组(P<0.05);两组间肿瘤缓解率比较差异无统计学意义(P>0.05);治疗组KPS评分改善情况优于对照组(P<0.05);治疗后两组组内CD3+、CD4+、CD4+/CD8+、NK细胞数量相比较均有显著性改善(P<0.05),两组间CD3+、CD4+、CD4+/CD8+、NK细胞数量相比较差异有统计学意义(P<0.05)。结论:加味连理汤有预防CPT-11所致迟发性腹泻、改善患者生活质量、提高免疫功能的作用。

Objective：To evaluate the preventive effect of Jiawei Lianli decoction on delayed-onset diarrhea caused by irinotecan. Methods：There were 62 patients with advanced colorectal cancer randomly divided into two group,30 in treatment group and 32 in control group. All the patients were given FOLFIRI chemotherapy. Patients in the treatment group were given Jiawei Lianli decoction for 10 days. After the treatment,the following changes in two groups were measured such as the incidence and severity of diarrhea,tumor remission rate,healthy state（Karnofsky score） and the immune function. Results：The treatment group showed significantly lower incidence rates of delayed-onset diarrhea and less severity of diarrhea than the control group（P〈0.05）. There was no difference between two groups on tumor remission rate（P〉0.05）. After the treatment,the CD3^＋,CD4^＋,CD4^＋/CD8^＋,natural killer cells and the Karnofsky score were increased in both groups,and they also showed differences between the 2 groups（P〈0.05）. Conclusion ：Jiawei Lianli decoction can prevent the delayed-onset diarrhea caused by irrinotecan,improve the quality of life,and enhance the immune function of the patients with advanced colorectal cancer.